S&P 500
6,005.88
+0.1%
+$5.52
DJI
42,761.76
-0.0%
-$1.11
NASDAQ
19,591.24
+0.3%
+$61.28
Bitcoin
109,527.00
+3.7%
+3,928.96
AAPL
$201.70
-1.1%
-$2.22
AMZN
$217.31
+1.8%
+$3.74
GOOG
$177.80
+1.8%
+$3.09
META
$694.90
-0.4%
-$2.81
MSFT
$472.75
+0.5%
+$2.37
NVDA
$142.74
+0.7%
+$1.02
TSLA
$308.41
+4.5%
+$13.27
Resverlogix (TSX: RVX)
CA$0.04
(12.5%)
CA$0.00
Price as of June 9, 2025, 3:36 p.m. ET
Resverlogix Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Resverlogix Company Info
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. It develops Apabetalone for diabetes mellitus, chronic kidney, peripheral artery, Orphan, and Alzheimer's diseases. The company was founded by Donald J. McCaffrey and Norman C. W. Wong on August 17, 2000 and is headquartered in Calgary, Canada.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.